| 7.9499 0.25 (3.25%) | 04-24 14:22 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.44 | 1-year : | 13.37 |
| Resists | First : | 9.8 | Second : | 11.44 |
| Pivot price | 8.16  |
|||
| Supports | First : | 7.13 | Second : | 5.93 |
| MAs | MA(5) : | 7.61  |
MA(20) : | 8.48 |
| MA(100) : | 10.13 |
MA(250) : | 8.94 |
|
| MACD | MACD : | -0.8 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 29.3 |
D(3) : | 19.4 |
| RSI | RSI(14): 39.6 |
|||
| 52-week | High : | 16.74 | Low : | 4.53 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RXRX ] has closed above bottom band by 45.3%. Bollinger Bands are 32.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.93 - 7.97 | 7.97 - 8.01 |
| Low: | 7.46 - 7.5 | 7.5 - 7.54 |
| Close: | 7.63 - 7.7 | 7.7 - 7.76 |
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Thu, 18 Apr 2024
Insider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Sells 11,447 Shares of Stock - MarketBeat
Wed, 17 Apr 2024
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Thu, 04 Apr 2024
Recursion Pharmaceuticals Inc Director Blake Borgeson Sells 11,447 Shares - Yahoo Finance
Wed, 27 Mar 2024
Should You Buy Recursion Pharmaceuticals Inc (RXRX) Stock Wednesday Morning? - InvestorsObserver
Thu, 21 Mar 2024
Recursion Pharmaceuticals director sells over $216k in company stock - Investing.com
Thu, 14 Mar 2024
1 AI Growth Stock With 54% Upside Potential - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 227 (M) |
| Shares Float | 188 (M) |
| Held by Insiders | 5.6 (%) |
| Held by Institutions | 93.6 (%) |
| Shares Short | 39,760 (K) |
| Shares Short P.Month | 42,820 (K) |
| EPS | -1.59 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.98 |
| Profit Margin | 0 % |
| Operating Margin | -919.3 % |
| Return on Assets (ttm) | -32.3 % |
| Return on Equity (ttm) | -69.2 % |
| Qtrly Rev. Growth | -20.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.19 |
| EBITDA (p.s.) | -1.44 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -288 (M) |
| Levered Free Cash Flow | -187 (M) |
| PE Ratio | -5.1 |
| PEG Ratio | -0.4 |
| Price to Book value | 4.06 |
| Price to Sales | 41.01 |
| Price to Cash Flow | -6.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|